- Home
- FOXX vs RFL Comparison
FOXX vs RFL Comparison
Compare FOXX & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOXX
- RFL
- Stock Information
- Founded
- FOXX 2017
- RFL 2017
- Country
- FOXX United States
- RFL United States
- Employees
- FOXX N/A
- RFL N/A
- Industry
- FOXX
- RFL Real Estate
- Sector
- FOXX
- RFL Finance
- Exchange
- FOXX Nasdaq
- RFL Nasdaq
- Market Cap
- FOXX 56.2M
- RFL 48.4M
- IPO Year
- FOXX N/A
- RFL N/A
- Fundamental
- Price
- FOXX $7.10
- RFL $1.84
- Analyst Decision
- FOXX
- RFL
- Analyst Count
- FOXX 0
- RFL 0
- Target Price
- FOXX N/A
- RFL N/A
- AVG Volume (30 Days)
- FOXX 27.7K
- RFL 26.3K
- Earning Date
- FOXX 11-29-2024
- RFL 12-12-2024
- Dividend Yield
- FOXX N/A
- RFL N/A
- EPS Growth
- FOXX N/A
- RFL N/A
- EPS
- FOXX N/A
- RFL N/A
- Revenue
- FOXX $3,228,559.00
- RFL $637,000.00
- Revenue This Year
- FOXX N/A
- RFL N/A
- Revenue Next Year
- FOXX N/A
- RFL N/A
- P/E Ratio
- FOXX N/A
- RFL N/A
- Revenue Growth
- FOXX N/A
- RFL 128.32
- 52 Week Low
- FOXX $6.59
- RFL $1.29
- 52 Week High
- FOXX $14.99
- RFL $2.50
- Technical
- Relative Strength Index (RSI)
- FOXX N/A
- RFL 46.69
- Support Level
- FOXX N/A
- RFL $1.74
- Resistance Level
- FOXX N/A
- RFL $1.96
- Average True Range (ATR)
- FOXX 0.00
- RFL 0.10
- MACD
- FOXX 0.00
- RFL -0.01
- Stochastic Oscillator
- FOXX 0.00
- RFL 40.00
About FOXX Foxx Development Holdings Inc. Common Stock
Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.